quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·142d
PRRelease
Jasper Therapeutics Inc. logo

Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

JSPR· Jasper Therapeutics Inc.
Health Care
Original source

Companies

  • JSPR
    Jasper Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Mar 23UpdateUBS$1.50
  • Jan 13UpdateRodman & Renshaw$17.00
  • Jul 8UpdateBMO Capital Markets$4.00
  • Jul 8UpdateRBC Capital Mkts$5.00
  • Jul 7UpdateCantor Fitzgerald-
  • Jul 7UpdateWilliam Blair-

Related

  • SEC24d
    Jasper Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • SEC24d
    SEC Form 10-K filed by Jasper Therapeutics Inc.
  • PR24d
    Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
  • ANALYST31d
    UBS resumed coverage on Jasper Therapeutics with a new price target
  • SEC57d
    SEC Form SCHEDULE 13G filed by Jasper Therapeutics Inc.
  • PR58d
    Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference
  • SEC64d
    Amendment: SEC Form SCHEDULE 13D/A filed by Jasper Therapeutics Inc.
  • SEC70d
    SEC Form SCHEDULE 13G filed by Jasper Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022